Table 4 Pathological Outcomes of men who had PSMA altering scan
Patient | MRI | Biopsy | PSMA | Treatment | Final Histology |
|---|---|---|---|---|---|
Patient 1 | PI-RADS 3 | GG1 | MRI occult lesion SUV max 7.73 | TP biopsy | GG1 |
Patient 2 | PI-RADS 3 | GG1 | MRI occult lesion, SUV max 3.73 | RARP | GG3, ECE, Cribiform, MRI occult lesion was index lesion |
Patient 3 | PI-RADS 4 | GG1 | Marked uptake, SUV max 8.1 | RARP | GG2 |
Patient 4 | PI-RADS 5 | GG1 | Marked uptake, SUV max 10.7 | RARP | GG2 |
Patient 5 | PI-RADS 5 | GG1 | Moderate uptake SUV max 5.4 | TP | GG1 |
Patient 6 | PI-RADS 5 | GG1 | Moderate uptake SUV max 5.3 | TP | GG1 |
Patient 7 | PI-RADS 3 | GG2 | Focal moderate uptake SUV max 5.98 | RARP | GG2, ECE |
Patient 8 | PI-RADS 4 | GG2 | MRI occult lesion, marked uptake SUV max 8.05 | RARP | GG2, cribiform, MRI occult lesion was index lesion |
Patient 9 | PI-RADS 4 | GG2 | Focal uptake, concerning for ECE, SUV max 5.6 | RARP | GG2, ECE, cribiform, |
Patient 10 | PI-RADS 4 | GG2 | Marked uptake SUV max 8.06 | RARP | GG2 |
Patient 11 | PIRADS 5 | GG2 | Marked uptake SUV max 8.42, ECE | RARP | GG3, Cribiform, Intraductal |
Patient 12 | PI-RADS 5 | GG2 | Marked uptake SUV max 6.66 | RARP | GG2 |
Patient 13 | PI-RADS 5 | GG2 | Marked uptake SUV max 7.94 ECE | RARP | GG2, ECE |
Patient 14 | PI-RADS 5 | GG2 | MRI occult lesion, SUV max 7.71 | RARP | GG2 |